{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:14:47Z","timestamp":1740147287535,"version":"3.37.3"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T00:00:00Z","timestamp":1702598400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T00:00:00Z","timestamp":1702598400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Advances in the treatment of biliary tract cancer have been made possible through gains in genomic and epigenetic tumor understanding. The use of fibroblast growth factor receptor inhibitor has enabled significant clinical improvement in a specific group of patients with intrahepatic cholangiocarcinoma, some of whom with very durable responses.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>We present the case of a 69-year-old Caucasian patient with advanced intrahepatic cholangiocarcinoma who received the therapy with selective oral inhibitor of fibroblast growth factor receptor 1, 2, and 3 pemigatinib after multiple previous chemotherapies. This resulted in a durable stable disease condition for 15\u00a0months with good tolerability. The diagnosis of acute myeloid leukemia was an unanticipated serious adverse event, in which the impact of fibroblast growth factor receptor inhibition could not yet be determined due to inadequate data.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>It is still possible to achieve durable tumor response in advanced previously treated intrahepatic cholangiocarcinoma through targeted therapies. The prolonged progression free survival\u00a0means that there could be an increased risk of secondary malignancy in this patient group, which necessitates diagnostic and therapeutic strategies.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13256-023-04231-2","type":"journal-article","created":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T01:02:05Z","timestamp":1702602125000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Durable response from fibroblast growth factor receptor inhibition in intrahepatic cholangiocarcinoma terminated by metachronous acute myeloid leukemia: a\u00a0case report"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4007-1730","authenticated-orcid":false,"given":"Andreas Edwin","family":"Juarso","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanie","family":"Entz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Weissinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,12,15]]},"reference":[{"issue":"9935","key":"4231_CR1","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1016\/S0140-6736(13)61903-0","volume":"383","author":"N Razumilava","year":"2014","unstructured":"Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet. 2014;383(9935):2168\u201379. https:\/\/doi.org\/10.1016\/S0140-6736(13)61903-0.","journal-title":"Lancet"},{"key":"4231_CR2","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","volume":"17","author":"JM Banales","year":"2020","unstructured":"Banales JM, Marin JJG, Lamarca A, et\u00a0al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17:557\u201388. https:\/\/doi.org\/10.1038\/s41575-020-0310-z.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"4231_CR3","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/nrc2780","volume":"10","author":"N Turner","year":"2010","unstructured":"Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 2010;10(2):116\u201329. https:\/\/doi.org\/10.1038\/nrc2780.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"4231_CR4","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/s41416-020-01157-0","volume":"124","author":"MA Krook","year":"2021","unstructured":"Krook MA, Reeser JW, Ernst G, Barker H, Wilberding M, Li G, Chen HZ, Roychowdhury S. Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance. Br J Cancer. 2021;124(5):880\u201392. https:\/\/doi.org\/10.1038\/s41416-020-01157-0.","journal-title":"Br J Cancer"},{"issue":"5","key":"4231_CR5","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa GK, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al-Rajabi R, Paulson AS, Borad MJ, Gallinson D, Murphy AG, Oh DY, Dotan E, Catenacci DV, Van Cutsem E, Ji T, Lihou CF, Zhen H, F\u00e9liz L, Vogel A. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020;21(5):671\u201384. https:\/\/doi.org\/10.1016\/S1470-2045(20)30109-1.","journal-title":"Lancet Oncol"},{"issue":"9","key":"4231_CR6","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1007\/s40265-020-01330-y","volume":"80","author":"SM Hoy","year":"2020","unstructured":"Hoy SM. Pemigatinib: first approval. Drugs. 2020;80(9):923\u20139. https:\/\/doi.org\/10.1007\/s40265-020-01330-y.","journal-title":"Drugs"},{"issue":"3","key":"4231_CR7","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2206834","volume":"388","author":"L Goyal","year":"2023","unstructured":"Goyal L, Meric-Bernstam F, Hollebecque A, Valle JW, Morizane C, Karasic TB, Abrams TA, Furuse J, Kelley RK, Cassier PA, Kl\u00fcmpen HJ, Chang HM, Chen LT, Tabernero J, Oh DY, Mahipal A, Moehler M, Mitchell EP, Komatsu Y, Masuda K, Ahn D, Epstein RS, Halim AB, Fu Y, Salimi T, Wacheck V, He Y, Liu M, Benhadji KA, Bridgewater JA, FOENIX-CCA2 Study Investigators. Futibatinib for\u00a0FGFR2-rearranged intrahepatic cholangiocarcinoma. N Engl J Med. 2023;388(3):228\u201339. https:\/\/doi.org\/10.1056\/NEJMoa2206834.","journal-title":"N Engl J Med"},{"issue":"10","key":"4231_CR8","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S2468-1253(21)00196-5","volume":"6","author":"M Javle","year":"2021","unstructured":"Javle M, Roychowdhury S, Kelley RK, Sadeghi S, Macarulla T, Weiss KH, Waldschmidt DT, Goyal L, Borbath I, El-Khoueiry A, Borad MJ, Yong WP, Philip PA, Bitzer M, Tanasanvimon S, Li A, Pande A, Soifer HS, Shepherd SP, Moran S, Zhu AX, Bekaii-Saab TS, Abou-Alfa GK. Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. Lancet Gastroenterol Hepatol. 2021;6(10):803\u201315. https:\/\/doi.org\/10.1016\/S2468-1253(21)00196-5.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"4231_CR9","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41416-018-0334-0","volume":"120","author":"V Mazzaferro","year":"2019","unstructured":"Mazzaferro V, El-Rayes BF, Droz DitBusset M, Cotsoglou C, Harris WP, Damjanov N, Masi G, Rimassa L, Personeni N, Braiteh F, Zagonel V, Papadopoulos KP, Hall T, Wang Y, Schwartz B, Kazakin J, Bhoori S, de Braud F, Shaib WL. Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma. Br J Cancer. 2019;120(2):165\u201371. https:\/\/doi.org\/10.1038\/s41416-018-0334-0.","journal-title":"Br J Cancer"},{"issue":"4_suppl","key":"4231_CR10","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1200\/JCO.2022.40.4_suppl.427","volume":"40","author":"MM Javle","year":"2022","unstructured":"Javle MM, Abou-Alfa GK, Macarulla T, Personeni N, Adeva J, Bergamo F, Malka D, Vogel A, Knox JJ, Evans TRJ, Dimova-Dobreva M, Harris WP, Saulay M, Engelhardt M, Braun S, Busset MDD, Borad MJ. Efficacy of derazantinib in intrahepatic cholangiocarcinoma patients with FGFR2 mutations or amplifications: interim results from the phase 2 study FIDES-01. J Clin Oncol. 2022;40(4_suppl):427\u2013427. https:\/\/doi.org\/10.1200\/JCO.2022.40.4_suppl.427.","journal-title":"J Clin Oncol"},{"key":"4231_CR11","doi-asserted-by":"publisher","unstructured":"Pant S, Schuler MH, Iyer G, Doi T, Qin S, Tabernero J, Arnold D, Gutierrez M, Prenen H, Folprecht G, Winter H, Cosman R, DalMolin GZ, Xia Q, Najmi S, Hammond C, Thomas S, Triantos S, Sweiti H, Loriot Y. Efficacy and safety of erdafitinib in adults with cholangiocarcinoma (CCA) with prespecified fibroblast growth factor receptor alterations (FGFRalt) in the phase 2 open-label, single-arm RAGNAR trial: expansion cohort results. J Clin Oncol 2023;41(4): 610\u2013610. https:\/\/doi.org\/10.1200\/JCO.2023.41.4_suppl.610.","DOI":"10.1200\/JCO.2023.41.4_suppl.610"},{"key":"4231_CR12","unstructured":"Sinn M, Arnold D, Borner M, Caca K, G\u00f6tze TO, Ricke J, Seehofer D, Stein A, Vogel A, Wege H, Weichert W, Winder T. Biliary carcinoma. Onkopedia. 2021 October.\u00a0https:\/\/www.onkopedia.com\/de\/onkopedia\/guidelines\/biliaere-karzinome\/@@guideline\/html\/index.html. Accessed May 16, 2023."},{"key":"4231_CR13","doi-asserted-by":"publisher","unstructured":"Vogel A, Bridgewater J, Edeline J, Kelley RK, Kl\u00fcmpen HJ, Malka D, Primrose JN, Rimassa L, Stenzinger A, Valle JW, Ducreux M; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(2):127\u2013140. https:\/\/doi.org\/10.1016\/j.annonc.2022.10.506","DOI":"10.1016\/j.annonc.2022.10.506"},{"issue":"15","key":"4231_CR14","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1182\/blood-2012-08-448068","volume":"121","author":"LM Morton","year":"2013","unstructured":"Morton LM, Dores GM, Tucker MA, Kim CJ, Onel K, Gilbert ES, Fraumeni JF Jr, Curtis RE. Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975\u20132008. Blood. 2013;121(15):2996\u20133004. https:\/\/doi.org\/10.1182\/blood-2012-08-448068.","journal-title":"Blood"},{"issue":"9","key":"4231_CR15","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1182\/bloodadvances.2021006239","volume":"6","author":"OK Weinberg","year":"2022","unstructured":"Weinberg OK, Siddon A, Madanat YF, Gagan J, Arber DA, Dal Cin P, Narayanan D, Ouseph MM, Kurzer JH, Hasserjian RP. TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS\/AML. Blood Adv. 2022;6(9):2847\u201353. https:\/\/doi.org\/10.1182\/bloodadvances.2021006239.","journal-title":"Blood Adv"},{"issue":"12","key":"4231_CR16","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, Ebert BL, Fenaux P, Godley LA, Hasserjian RP, Larson RA, Levine RL, Miyazaki Y, Niederwieser D, Ossenkoppele G, R\u00f6llig C, Sierra J, Stein EM, Tallman MS, Tien HF, Wang J, Wierzbowska A, L\u00f6wenberg B. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345\u201377. https:\/\/doi.org\/10.1182\/blood.2022016867.","journal-title":"Blood"},{"issue":"4","key":"4231_CR17","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1817323","volume":"381","author":"Y Loriot","year":"2019","unstructured":"Loriot Y, Necchi A, Park SH, Garcia-Donas J, Huddart R, Burgess E, Fleming M, Rezazadeh A, Mellado B, Varlamov S, Joshi M, Duran I, Tagawa ST, Zakharia Y, Zhong B, Stuyckens K, Santiago-Walker A, De Porre P, O\u2019Hagan A, Avadhani A, Siefker-Radtke AO, BLC2001 Study Group. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med. 2019;381(4):338\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1817323.","journal-title":"N Engl J Med"},{"issue":"16_suppl","key":"4231_CR18","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.1200\/JCO.2022.40.16_suppl.3007","volume":"40","author":"Y Loriot","year":"2022","unstructured":"Loriot Y, Schuler M, Iyer G, Witt O, Doi T, Qin S, Tabernero J, Reardon DA, Massard C, Palmer D, Lugowska I, Coward J, Corassa M, Stuyckens K, Liao H, Najmi S, Hammond C, Santiago-Walker AE, Sweiti H, Pant S. Tumor agnostic efficacy and safety of erdafitinib in patients (pts) with advanced solid tumors with prespecified fibroblast growth factor receptor alterations (FGFRalt) in RAGNAR: interim analysis (IA) results. J Clin Oncol. 2022;40(16_suppl):3007. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.3007.","journal-title":"J Clin Oncol"},{"issue":"6","key":"4231_CR19","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1182\/blood-2016-10-695973","volume":"129","author":"A Reiter","year":"2017","unstructured":"Reiter A, Gotlib J. Myeloid neoplasms with eosinophilia. Blood. 2017;129(6):704\u201314. https:\/\/doi.org\/10.1182\/blood-2016-10-695973.","journal-title":"Blood"},{"issue":"13","key":"4231_CR20","doi-asserted-by":"publisher","first-page":"3136","DOI":"10.1182\/bloodadvances.2020002308","volume":"4","author":"M Kasbekar","year":"2020","unstructured":"Kasbekar M, Nardi V, Dal Cin P, Brunner AM, Burke M, Chen YB, Connolly C, Fathi AT, Foster J, Macrae M, McAfee SL, McGregor K, Narayan R, Ramos AY, Som TT, Vartanian M, Friedman RS, Benhadji KA, Hobbs GS. Targeted FGFR inhibition results in a durable remission in an FGFR1-driven myeloid neoplasm with eosinophilia. Blood Adv. 2020;4(13):3136\u201340. https:\/\/doi.org\/10.1182\/bloodadvances.2020002308.","journal-title":"Blood Adv"},{"key":"4231_CR21","doi-asserted-by":"publisher","unstructured":"Javidi-Sharifi N, Martinez J, English I, Joshi SK, Scopim-Ribeiro R, Viola SK, Edwards DK 5th, Agarwal A, Lopez C, Jorgens D, Tyner JW, Druker BJ, Traer E. FGF2-FGFR1 signaling regulates release of leukemia-protective exosomes from bone marrow stromal cells. Elife. 2019;8:e40033. https:\/\/doi.org\/10.7554\/eLife.40033. Erratum in: Elife. 2019;8.","DOI":"10.7554\/eLife.40033"},{"issue":"Supplement 1","key":"4231_CR22","doi-asserted-by":"publisher","first-page":"3980","DOI":"10.1182\/blood-2022-163099","volume":"140","author":"S Verstovsek","year":"2022","unstructured":"Verstovsek S, Gotlib J, Vannucchi AM, Rambaldi A, Reiter A, Shomali W, George TI, Patel JL, Colucci P, Zhen H, Oliveira N, Kiladjian J-J. FIGHT-203, an ongoing phase 2 study of pemigatinib in patients with myeloid\/lymphoid neoplasms (MLNs) with fibroblast growth factor receptor 1 (FGFR1) rearrangement (MLNFGFR1): a focus on centrally reviewed clinical and cytogenetic responses in previously treated patients. Blood. 2022;140(Supplement 1):3980\u20132. https:\/\/doi.org\/10.1182\/blood-2022-163099.","journal-title":"Blood"},{"key":"4231_CR23","unstructured":"FGFR1 fibroblast growth factor receptor 1 [Homo sapiens (human)]. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; 2004. https:\/\/www.ncbi.nlm.nih.gov\/gene\/2260#additional-links. Accessed 07 Aug 2023."},{"key":"4231_CR24","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12885-022-10421-w","volume":"23","author":"A Haslam","year":"2023","unstructured":"Haslam A, Olivier T, Tuia J, et\u00a0al. Umbrella review of basket trials testing a drug in tumors with actionable genetic biomarkers. BMC Cancer. 2023;23:46. https:\/\/doi.org\/10.1186\/s12885-022-10421-w.","journal-title":"BMC Cancer"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-023-04231-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-023-04231-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-023-04231-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T10:04:58Z","timestamp":1704362698000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-023-04231-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,15]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4231"],"URL":"https:\/\/doi.org\/10.1186\/s13256-023-04231-2","relation":{},"ISSN":["1752-1947"],"issn-type":[{"type":"electronic","value":"1752-1947"}],"subject":[],"published":{"date-parts":[[2023,12,15]]},"assertion":[{"value":"2 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Open Access funding by Projekt DEAL was not included in the original publication, this article has been updated.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Local ethics approval was not required at the time for the compassionate use program for pemigatinib. The patient provided informed written consent for the compassionate use program for pemigatinib.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient\u2019s next-of-kin for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"550"}}